Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Aarcoron Sep 24, 2019 9:02pm
132 Views
Post# 30161256

RE:I agree, it's very very terrible

RE:I agree, it's very very terribleJD, here's the trouble with your flippant responses - setting aside that you're an apparent shareholder, as a paid Communications Director you never address that Bioasis CEOs have never been able to navigate the financial aspects of the business.  Each one of them has failed horribly.  Aside from building the trial models and leading the medical direction, CEOs are paid to build respected teams, to craft a potentially valuable and viable financial plan and execute on time. That hasn't happened.  So much apparent promise in this company's pipeline and our CEOs can't get one pharma that will take a material long term funding position ?  They all resort to pathetic financings that leave the most recent investors saying WTF, and the ones previous stacking a perpetual wall of shares for sale.

The leadership has just been a total fail on the business side and you support them publically without pause.  That makes you look like a shill and a "promoter" and it's one of the reasons I suggested to you long ago to stick to the science.

I'm not moving on from this stock as I have a perpetual warrant at I think 24 cents today, but I have no interest in letting this awful leadership carry on without letting them know they have and are doing this company a terrible disservice by constantly leaving every previous PP subscriber and retail investor holding the bag.

Our current CEO and this BoD needs to do much better or GTFO.
Bullboard Posts